Phase 3 non-inferiority RCT in 557 virologically suppressed adults with HIV-1 on complex regimens: switching to bictegravir-lenacapavir was non-inferior for HIV-1 RNA ≥50 copies/mL at week 48 (1% vs 1%); 5 deaths with switch, none drug-related.
RCTn = 557
Orkin et al. Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial